Steve Scala
Stock Analyst at TD Cowen
(1.85)
# 1,867
Out of 4,496 analysts
26
Total ratings
79.17%
Success rate
15.34%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Upgrades: Outperform | $125 → $135 | $125.77 | +7.34% | 1 | Jan 4, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $29.97 | +6.77% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $80 → $66 | $42.64 | +54.78% | 1 | Sep 15, 2023 | |
| RHHBY Roche Holding AG | Maintains: Market Perform | $45 → $40 | $39.27 | +1.86% | 4 | Sep 12, 2023 | |
| LLY Eli Lilly | Maintains: Outperform | $430 → $500 | $857.47 | -41.69% | 6 | May 23, 2023 | |
| ABBV AbbVie | Maintains: Outperform | $150 → $180 | $172.32 | +4.46% | 9 | Apr 14, 2022 | |
| NVS Novartis AG | Downgrades: Market Perform | n/a | $106.13 | - | 3 | Feb 1, 2021 | |
| RPRX Royalty Pharma | Initiates: Outperform | n/a | $28.14 | - | 1 | Jul 13, 2020 |
Merck & Co.
Jan 4, 2024
Upgrades: Outperform
Price Target: $125 → $135
Current: $125.77
Upside: +7.34%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $29.97
Upside: +6.77%
Bristol-Myers Squibb Company
Sep 15, 2023
Maintains: Market Perform
Price Target: $80 → $66
Current: $42.64
Upside: +54.78%
Roche Holding AG
Sep 12, 2023
Maintains: Market Perform
Price Target: $45 → $40
Current: $39.27
Upside: +1.86%
Eli Lilly
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $857.47
Upside: -41.69%
AbbVie
Apr 14, 2022
Maintains: Outperform
Price Target: $150 → $180
Current: $172.32
Upside: +4.46%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $106.13
Upside: -
Royalty Pharma
Jul 13, 2020
Initiates: Outperform
Price Target: n/a
Current: $28.14
Upside: -